Mr Madsen joined Novavax in 2008 as director of BioProcess Development with responsibility for development of Novavax’s seasonal and pandemic influenza vaccines for clinical testing. Earlier, he was director of manufacturing for the vaccine clinical materials program at SAIC-Frederick, and director of pharmaceutical science at Entremed.
Mr Pincus joined Novavax in 2007 as director of analytical development with responsibility for product validation in support of preclinical and clinical studies. Previously, he was senior director of virology and animal biology at Elusys Therapeutics, and senior research scientist with Virogenetics.
Mr Madsen and Mr Pincus will report to Rahul Singhvi, CEO of Novavax.
Mr Singhvi said: “John and Steve are uniquely well-qualified to manage our manufacturing process development, and quality organizations. Under their guidance and support, we have scaled up VLP vaccine manufacturing in large-scale stirred tank bioreactors, doubled our vaccine production capacity in our pilot manufacturing facility, substantially reduced manufacturing costs and advanced plans to commercialize our vaccine candidates.
“These achievements reflect their leadership skills, as well as the talent and dedication of their teams, and will be critical to our future success.”